ERYTECH Pharma S.A. (ERYP) Analysts See $-0.59 EPS

August 12, 2018 - By Sheila Anderson

Analysts expect ERYTECH Pharma S.A. (NASDAQ:ERYP) to report $-0.59 EPS on August, 21. The stock decreased 2.29% or $0.24 during the last trading session, reaching $10.24. About 1,150 shares traded. ERYTECH Pharma S.A. (NASDAQ:ERYP) has 0.00% since August 13, 2017 and is . It has underperformed by 12.57% the S&P500.

ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. The company has market cap of $190.43 million. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. It currently has negative earnings. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.

More news for ERYTECH Pharma S.A. (NASDAQ:ERYP) were recently published by: Nasdaq.com, which released: “ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 2018” on July 17, 2018. Globenewswire.com‘s article titled: “Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2018” and published on August 06, 2018 is yet another important article.

ERYTECH Pharma S.A. (NASDAQ:ERYP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.